Actively Recruiting

Phase 3
Age: 20Years - 70Years
FEMALE
NCT07350928

Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status

Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-01-20

394

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

Sponsors

T

Tianjin Medical University Cancer Institute and Hospital

Lead Sponsor

S

Shanghai Hengrui Pharmaceutical Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This clinical trial aims to evaluate the efficacy and safety of Dexmedetomidine Hydrochloride Nasal Spray for conscious sedation and anxiety relief during breast-conserving surgery. The main questions it aims to answer are: Does Dexmedetomidine Hydrochloride Nasal Spray effectively provide intraoperative sedation and improve postoperative awakening time? What changes in vital signs or postoperative complications do participants experience when using this medication? Researchers will compare Dexmedetomidine Hydrochloride Nasal Spray to a placebo (saline nasal spray) to determine its efficacy in breast-conserving surgery. Participants will: Receive preoperative administration of either Dexmedetomidine Hydrochloride Nasal Spray or the placebo nasal spray; Undergo regular intraoperative and postoperative assessments, including sedation scores, awakening time, and pain scores; Provide satisfaction feedback and be monitored for changes in vital signs and complications.

CONDITIONS

Official Title

Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status

Who Can Participate

Age: 20Years - 70Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Female patients aged between 20 and 70 years
  • Classified as ASA I or II (American Society of Anesthesiologists physical status)
  • Body mass index (BMI) between 18 and 26 kg/m²
Not Eligible

You will not qualify if you...

  • Unsuitable for nasal spray administration (e.g., severe rhinitis, nasal deformities)
  • Severe bradycardia (heart rate < 50 beats/min) or history of cardiac conduction block
  • History of upper respiratory tract infection
  • History of asthma
  • Allergy to Dexmedetomidine or local anesthetics
  • Prior use of anti-anxiety medication before surgery
  • History of ischemic stroke or transient ischemic attack
  • Poorly controlled blood pressure despite medication
  • History of mental illness, cognitive impairment, or epilepsy
  • History of pregnancy
  • Long-term use of sedatives or analgesics
  • History of liver or kidney function impairment
  • History of drug or alcohol abuse
  • Any other conditions deemed disqualifying by the study reviewers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tianjin Medical University Cancer Institute and Hospital

Tianjin, China, 300060

Actively Recruiting

Loading map...

Research Team

Y

Yajing Yuan

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here